

**CORRECTED
VERSION***

PCT



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, C12N 15/11, A61K 38/17, 31/70, C12Q 1/68, G01N 33/68, A61K 48/00		A2	(11) International Publication Number: WO 99/36536 (43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/US99/01087 (22) International Filing Date: 19 January 1999 (19.01.99)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/071,950 20 January 1998 (20.01.98) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): BLOOD CENTER RESEARCH FOUNDATION [US/US]; 638 North 18th Street, P.O. Box 2178, Milwaukee, WI 53233 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SIMS, Peter, J. [US/US]; 13386 Caminito Mar Villa, Del Mar, CA 92014 (US); WIEDMER, Therese [US/US]; 13386 Caminito Mar Villa, Del Mar, CA 92014 (US). ZHAO, Ji [US/US]; Apartment 105, 309 North Solano Hills Drive, Solano, CA 92075 (US).			
(74) Agent: BAKER, Jean, C.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).			
(54) Title: METHODS AND COMPOSITIONS TO ALTER TISSUE SUSCEPTIBILITY TO IMMUNE INJURY, TO PROGRAMMED CELL DEATH, AND TO CLEARANCE BY THE RETICULOENDOTHELIAL SYSTEM			
(57) Abstract			
<p>A method for extending the viability of mammalian cells or tissues comprising the step of inhibiting the expression of native PL scramblase within the cell or tissue is disclosed. In another embodiment of the invention, a method of decreasing the viability, metastatic or invasive potential of cancer cells, cancerous tissue, or viral-infected cell by causing increased expression or activity of PL scramblase protein within the cell or tissue is disclosed.</p>			
<pre> MUR 10 20 30 40 50 MEAPRSGTYLPAGYAPQYPPAAVQGPPEHTGRPTFQTNYQVPQSGYPGPQASY HUM 10 20 30 40 50 MDKQNSQMNASHPETNLPGVQYPPTAFQGPPGYSGYGPQVSYPPPAGHSGPQPA MUR 60 70 80 90 100 110 TVSTSGHEGYAATRLPIQNNOTIVLANTQWMPAPPILNCPPGLEYLNQIDOLLIHQVE HUM 60 70 80 90 100 110 GFPVNQPVYNQ---PV-YNQPVGAGVFWMPAPQPPLNCPGLEYLSQIDQILIHQQIE MUR 120 130 140 150 160 170 LLEVLTGFETNNKFEIKNSLGQMIVYVAVEDTDCCTRNCCEASRPFTLRLILDHLGQEVMTL HUM 120 130 140 150 160 170 LLEVLTGFETNNKYEIKNSFGQRVYFAAEVDCCTRNCGSPRFTLRLIDDNMGQEVTI MUR 180 190 200 210 220 230 ERPLRCSSCCFPCCLOEIEIQAPPGVPIGYVTQWTWHPLCPKLTQLNDKRENVLKVVGPCV HUM 180 190 200 210 220 230 ERPLRCSSCCCPCCLOEIEIQAPPGVPIGYVIQIWHPCLPKFTIQNEKREDVLKISGPCV MUR 240 250 260 270 280 290 ACTCCSDIDFEIKSLDEVTRIGKITKOWSGCVKEAFT<u>DSDNF</u>G10FPLDLEVKMKAVTLG HUM 240 250 260 270 280 290 VCSCCGDVDFEIKSLDEQCVVGKISKHWGILREAFT<u>DADNF</u>G10FPLDLDVKMKAVNIG MUR 300 <u>ACFLIDYMFFEGCE</u> HUM 300 <u>ACFL1DFMFESTGSQEOKSGVW</u> </pre>			